SpeeDx Begins Multisite U.S. Clinical Trials of ResistancePlus® MG Test SYDNEY, Australia, Sept. 25, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not...

UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted...

Clinical data demonstrates significantly increased cure rates using Resistance Guided Therapy for treating the STI Superbug M. genitalium SYDNEY, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced clinical data contained in a new study published in the June 2018 issue of Clinical Infectious Diseases1 [ link]...

SpeeDx receives FDA clearance for Mycoplasma genitalium product SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx’s ResistancePlus® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United...

SpeeDx Pty. Ltd. establishes US-based operation SYDNEY, Australia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd, a developer of advanced multiplex molecular diagnostic solutions, announced the incorporation of a US-based subsidiary company,...